Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaDrAZ: MDA for Malaria Elimination in Zanzibar
NCT02721186Completed
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dihydroartemisinin + piperaquine and primaquine in malaria (2 arms). Primary endpoint: Cumulative notified malaria incidence at 6 months. Started Apr 2016; status: completed.
02
Drugs
dihydroartemisinin + piperaquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02721186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721186.